Patent ID: 8895001

Claim:
A method of treating triple negative breast cancer which expresses ErbB3, the method comprising: identifying a patient with a triple negative breast cancer tumor, and administering to the identified patient an effective amount of an anti-cancer agent comprising an anti-ErbB3 antibody that comprises, in amino terminal to carboxy terminal order, a V H CDR1 sequence as shown in SEQ ID NO:3, a V H CDR2 sequence as shown in SEQ ID NO:4 and a V H CDR3 sequence as shown in SEQ ID NO:5, and, in amino terminal to carboxy terminal order, a V L CDR1 sequence as shown in SEQ ID NO:6, a V L CDR2 sequence as shown in SEQ ID NO:7 and a V L CDR3 sequence as shown in SEQ ID NO:8.